X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (35599) 35599
Dissertation (11) 11
Book Chapter (10) 10
Publication (6) 6
Book / eBook (4) 4
Conference Proceeding (4) 4
Web Resource (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (33330) 33330
humans (32185) 32185
xenograft model antitumor assays (30691) 30691
mice (28400) 28400
cell line, tumor (20972) 20972
oncology (16376) 16376
female (15786) 15786
mice, nude (15734) 15734
cancer (11918) 11918
apoptosis (10270) 10270
male (9473) 9473
cell proliferation - drug effects (7947) 7947
antineoplastic agents - pharmacology (7719) 7719
expression (7586) 7586
mice, inbred balb c (7556) 7556
tumors (7391) 7391
apoptosis - drug effects (7164) 7164
xenografts (5259) 5259
cell proliferation (5048) 5048
chemotherapy (4702) 4702
metastasis (4551) 4551
mice, scid (4459) 4459
tumor cells, cultured (4249) 4249
cell biology (4242) 4242
growth (4184) 4184
disease models, animal (3977) 3977
cells (3900) 3900
proteins (3879) 3879
analysis (3747) 3747
gene expression regulation, neoplastic (3738) 3738
gene expression (3601) 3601
research (3594) 3594
signal transduction - drug effects (3551) 3551
activation (3483) 3483
signal transduction (3429) 3429
therapy (3418) 3418
cell survival - drug effects (3389) 3389
inhibition (3334) 3334
pharmacology & pharmacy (3316) 3316
breast cancer (3240) 3240
cancer therapies (3108) 3108
biochemistry & molecular biology (3098) 3098
health aspects (3072) 3072
care and treatment (3025) 3025
kinases (3014) 3014
angiogenesis (2956) 2956
blotting, western (2809) 2809
antineoplastic agents - therapeutic use (2768) 2768
phosphorylation (2746) 2746
in-vivo (2681) 2681
gene expression regulation, neoplastic - drug effects (2660) 2660
cell cycle (2629) 2629
dose-response relationship, drug (2622) 2622
in-vitro (2618) 2618
medicine, research & experimental (2543) 2543
drug synergism (2537) 2537
tumor burden - drug effects (2527) 2527
multidisciplinary sciences (2416) 2416
carcinoma (2372) 2372
breast neoplasms - pathology (2354) 2354
breast-cancer (2235) 2235
immunohistochemistry (2233) 2233
proliferation (2227) 2227
medicine (2179) 2179
research article (2176) 2176
genetic aspects (2117) 2117
cytotoxicity (2112) 2112
flow cytometry (2101) 2101
cell growth (2073) 2073
resistance (2071) 2071
middle aged (2046) 2046
research paper (1976) 1976
breast neoplasms - drug therapy (1972) 1972
transfection (1936) 1936
mice, inbred nod (1935) 1935
mutation (1934) 1934
protein kinase inhibitors - pharmacology (1932) 1932
lung neoplasms - pathology (1871) 1871
antineoplastic agents - administration & dosage (1866) 1866
survival (1823) 1823
lung neoplasms - drug therapy (1822) 1822
rna interference (1816) 1816
xenograft model antitumor assays - methods (1806) 1806
lung cancer (1787) 1787
reverse transcriptase polymerase chain reaction (1785) 1785
prognosis (1752) 1752
antineoplastic agents - chemistry (1737) 1737
development and progression (1725) 1725
pathway (1711) 1711
nanoparticles (1689) 1689
neoplasms - drug therapy (1684) 1684
metastases (1671) 1671
animal models (1667) 1667
antineoplastic combined chemotherapy protocols - pharmacology (1646) 1646
down-regulation (1643) 1643
science (1604) 1604
time factors (1600) 1600
xenotransplantation (1589) 1589
cancer research (1573) 1573
cell movement - drug effects (1556) 1556
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (35417) 35417
Chinese (406) 406
Japanese (93) 93
Russian (28) 28
French (18) 18
German (6) 6
Hungarian (4) 4
Portuguese (4) 4
Spanish (3) 3
Italian (2) 2
Amharic (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International Journal of Cancer, ISSN 0020-7136, 09/2014, Volume 135, Issue 6, pp. 1487 - 1496
.... Regorafenib was tested alone and in combination with irinotecan in patient‐derived (PD) CRC models and a murine CRC liver metastasis model... 
regorafenib | CRC | multikinase inhibitor | antimetastasis | antitumorigenesis | MULTICENTER | METASTASIS | BEVACIZUMAB | RECEPTOR | COLON | CHEMOTHERAPY | PHASE-II TRIAL | ONCOLOGY | IRINOTECAN | EXPRESSION | ENDOTHELIAL GROWTH-FACTOR | Liver Neoplasms, Experimental - secondary | Humans | Drug Resistance, Neoplasm | Male | Organoplatinum Compounds - pharmacology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Liver Neoplasms, Experimental - metabolism | Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors | Neoplasm Metastasis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | Colorectal Neoplasms - metabolism | Camptothecin - analogs & derivatives | Pyridines - administration & dosage | Cell Growth Processes - drug effects | Mice, Inbred C57BL | Vascular Endothelial Growth Factor Receptor-2 - metabolism | Random Allocation | Vascular Endothelial Growth Factor Receptor-3 - metabolism | Xenograft Model Antitumor Assays | Animals | Liver Neoplasms, Experimental - drug therapy | Phenylurea Compounds - administration & dosage | Mice, Nude | Cell Line, Tumor | Mice | Phenylurea Compounds - pharmacology | Pyridines - pharmacology | Colorectal Neoplasms - pathology | Vascular Endothelial Growth Factor Receptor-3 - antagonists & inhibitors | Immunohistochemistry | Models | Vascular endothelial growth factor | Analysis | Colorectal cancer | Cancer therapies | Metastasis | Cancer Therapy
Journal Article
International journal of cancer, ISSN 0020-7136, 2016, Volume 139, Issue 9, pp. 2047 - 2055
Bromodomain and extraterminal (BET) bromodomain (BRD) proteins are epigenetic readers that bind to acetylated lysine residues on chromatin, acting as... 
blood brain barrier | glioblastoma | BET inhibitor | OTX015 (MK‐8628) | combination studies | Combination studies | Blood brain barrier | Glioblastoma | OTX015 (MK-8628) | SELECTIVE-INHIBITION | C-MYC | ACUTE MYELOID-LEUKEMIA | MALIGNANT GLIOMA | ONCOLOGY | RECURRENT | BROMODOMAIN INHIBITION | TARGETS | PROTEINS | SMALL-MOLECULE INHIBITION | BRD4 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Acetanilides - administration & dosage | Heterocyclic Compounds, 3-Ring - pharmacology | Humans | Everolimus - administration & dosage | Antineoplastic Agents - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dacarbazine - pharmacology | Dacarbazine - analogs & derivatives | Camptothecin - administration & dosage | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Camptothecin - analogs & derivatives | Cell Survival - drug effects | Acetanilides - pharmacology | Dacarbazine - administration & dosage | Everolimus - pharmacology | Brain Neoplasms - drug therapy | Blood-Brain Barrier - drug effects | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Heterocyclic Compounds, 3-Ring - administration & dosage | Cell Line, Tumor | Cell Proliferation - drug effects | Mice | Glioblastoma - drug therapy | Camptothecin - pharmacology | Epigenetic inheritance | Chemotherapy | Chromatin | RNA | Lysine | Analysis | Brain tumors | Gene expression | Glioblastoma multiforme | Protein binding | Cancer | Epigenetics | Cancer therapies | Brain cancer | Tumors
Journal Article
Journal Article
Molecular cancer therapeutics, ISSN 1538-8514, 2014, Volume 13, Issue 12, pp. 2910 - 2918
...). Recently, some RET and ROS1 fusion genes have been implicated as driver oncogenes in NSCLC and have become molecular targets for antitumor agents... 
ALK | GENE FUSIONS | CABOZANTINIB | IN-VITRO | ONCOLOGY | MUTATION | CRIZOTINIB | TYROSINE KINASE INHIBITOR | MEDULLARY-THYROID CARCINOMA | IDENTIFICATION | CCDC6-RET FUSION | Lung Neoplasms - drug therapy | Carbazoles - chemistry | Oncogene Proteins, Fusion - metabolism | Cytoskeletal Proteins - genetics | Humans | Molecular Conformation | Carbazoles - administration & dosage | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - chemistry | Piperidines - pharmacology | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Cytoskeletal Proteins - metabolism | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins c-ret - antagonists & inhibitors | Disease Models, Animal | Lung Neoplasms - genetics | Proto-Oncogene Proteins - antagonists & inhibitors | Piperidines - administration & dosage | Piperidines - chemistry | Carcinoma, Non-Small-Cell Lung - genetics | Models, Molecular | Antineoplastic Agents - chemistry | Proto-Oncogene Proteins c-ret - chemistry | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Signal Transduction - drug effects | Oncogene Proteins, Fusion - genetics | Gene Rearrangement | Cell Line, Tumor | Oncogene Proteins, Fusion - antagonists & inhibitors | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Carbazoles - pharmacology | Protein-Tyrosine Kinases - antagonists & inhibitors | Proto-Oncogene Proteins c-ret - genetics
Journal Article
Nature medicine, ISSN 1546-170X, 2013, Volume 19, Issue 2, pp. 202 - 208
Journal Article
Cancer Letters, ISSN 0304-3835, 2013, Volume 340, Issue 1, pp. 97 - 103
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 2009, Volume 69, Issue 24, pp. 9330 - 9336
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4793 - 4804
Journal Article
Journal Article
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2013, Volume 110, Issue 27, pp. 11103 - 11108
Journal Article